Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius ag - l-alanyl-l glutamine - concentrate for solution for infusion - 200 milligram(s)/millilitre - amino acids; alanyl glutamine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi deutschland gmbh - n(2)-l-alanyl-l-glutamine 10 g/50 ml - concentrate for solution for infusion - 200 mg/ml - n(2)-l-alanyl-l-glutamine 200 mg/ml - alanyl glutamine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi deutschland gmbh - n(2)-l-alanyl-l-glutamine 10 g/50 ml - concentrate for solution for infusion - 200 mg/ml - n(2)-l-alanyl-l-glutamine 200 mg/ml - alanyl glutamine

Singapore - English - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - n(2)-l-alanyl-l-glutamine - injection - 20 g/100ml - n(2)-l-alanyl-l-glutamine 20 g/100ml

Australia - English - Department of Health (Therapeutic Goods Administration)

fit-bioceuticals limited - glutamine -

Australia - English - Department of Health (Therapeutic Goods Administration)

herbs of gold pty ltd - glutamine -

United States - English - NLM (National Library of Medicine)

emmaus medical, inc. - glutamine (unii: 0rh81l854j) (glutamine - unii:0rh81l854j) - glutamine 5 g - endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. none risk summary there are no available data on endari use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. animal reproduction studies were not conducted with endari. adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. the background risk of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data on the presence of endari in human milk, the effect on the breastfed infant or the effect on milk production. the developmental and health benefits from breastfeeding should be considered along with the mother's clinical need for endari and any potential advers

Israel - English - Ministry of Health

cure medical & technical supply - l - glutamine; l- alanine - concentrate for solution for infusion - l- alanine 8.2 g / 100 ml; l - glutamine 13.46 g / 100 ml - glutamic acid hydrochloride - glutamic acid hydrochloride - dipeptiven is indicated as part of an intravenous parenteral nutrition regimen as a supplement to amino acid solutions or an amino acid containing infusion regimen.in patients in extreme cases of hypercatabolic stage such as major abdominal surgery, bmt, diffuse injury of gi mucous.

Israel - English - Ministry of Health

cure medical & technical supply - l - glutamine; l- alanine - concentrate for solution for infusion - l- alanine 8.2 g / 100 ml; l - glutamine 13.46 g / 100 ml - glutamic acid hydrochloride - dipeptiven is indicated as part of an intravenous parenteral nutrition regimen as a supplement to amino acid solutions or an amino acid containing infusion regimen.in patients in extreme cases of hypercatabolic stage such as major abdominal surgery, bmt, diffuse injury of gi mucous.

Israel - English - Ministry of Health

cure medical & technical supply - l - glutamine; l- alanine - concentrate for solution for infusion - l- alanine 8.2 g / 100 ml; l - glutamine 13.46 g / 100 ml - glutamic acid hydrochloride - dipeptiven is indicated as part of an intravenous parenteral nutrition regimen as a supplement to amino acid solutions or an amino acid containing infusion regimen.in patients in extreme cases of hypercatabolic stage such as major abdominal surgery, bmt, diffuse injury of gi mucous.